Online Safety Community

How current regulations effect product development strategies

The life sciences market in Japan, consisting of pharmaceuticals, medical devices, biologics and combination products, is huge by the standards of the markets in the neighborhood, such as China, Malaysia, Singapore and Australia. It compares with those of Europe and North America. The main reasons attributed for this are the high spending power of the population, high number and density of the population, the aging population and the huge spending on the healthcare sector on R and D and innovation, which result in high costs that have to be passed on to the consumer.


At this point of time, Japan is going through developments that have the potential to cause tremors, if not turbulence, in the life sciences market, particularly that of drugs. The annual potential for only drugs is pegged at ¥ 150 billion. In the backdrop of high unit prices of drugs, the government is keen to actively pursue a couple of major initiatives.

One, it wants to cut the price of generics, so that they reach out to a larger market base. Two, it wants to bring about improvements into the regulatory framework by focusing on regulations that ensure higher and easier postmarketing safety. The Japanese regulatory agency, the Pharmaceuticals and Medical Devices Agency (PMDA), is stepping up efforts to make changes into their IT systems, which will streamline the processes for filing clinical data for regulatory approval.

Makeover of its image

The PMDA also plans to recruit more manpower to tighten the overall regulatory process and bolster innovation in this sector to take it to even higher standards than it currently is in. the main purpose for which the PMDA is pushing for all these is to eradicate the impression that has gained ground, especially among western life sciences companies, that Japanese regulatory processes are laggardly and not up to the standards that can be expected from a country of its developmental level.

It is in the backdrop of these contexts that understanding what it takes to make regulatory filings in the life sciences in Japan acquires significance. An in-depth understanding of this topic will be the content of a webinar that is being organized by Compliance4All, a leading provider of professional trainings for all the areas of regulatory compliance.

At this webinar, Robert J. Russell, who is President of RJR Consulting, Inc., which assists the pharmaceutical, medical device and biotech industries in understanding and complying with International Regulations affecting compliance, new product development, manufacturing and Quality Assurance, will be the speaker.

To gain insights into how the regulatory filing requirements and compliance processes for Japan work, please enroll for this webinar by visiting

Insights into the regulatory scene

At this session, Robert J. Russell will familiarize participants with the regulatory compliance requirements and procedures for pharmaceuticals, medical devices, biologics and combination products in Japan. He will help participants get an understanding of topics relating to pre-clinical and clinical requirements, as well as with the structure of the regulatory agencies in Japan.

While elaborating on the current regulatory climate in Japan; the speaker will offer examples of effective compliance procedures and techniques. He will describe the methods by which regulators in the corresponding agencies process filings and registrations and what is expected in the authorization and dossier maintenance of licensed products and familiarize participants with a few common issues and concerns that professionals and firms dealing with Life Sciences usually face when they do business with Japan.

Japan’s utilization of the ICH standards

The speaker will also explain how Japan interacts with and utilizes ICH standards. He will also describe how Japan’s way of working with other national regulatory agencies influences their business. The webinar will show ways by which to address the conflicts that sometimes arise and suggest the optimal ways of doing this.

This course will provide insights into all the important areas of regulatory filing requirements and compliance processes for the life sciences in Japan. Its objectives are the following:

What is the Regulatory Structure in Japan
Understanding the specific procedures for Pharmaceuticals, Medical Devices, Biologics and Combination Products
How to begin your company involvement in Japan
How current regulations effect product development strategies
Pricing issues
Understanding the concerns/issues of Japanese Regulatory Personnel
Understanding the Local Culture: How to negotiate with the regulators
Information necessary for effective submissions
Maintenance of Authorized Products

This is the outline for the course:

Japan’s Regulatory Structure for the Life Science Product Industries
Beginning Your Company Involvement in Japan
Life Science Regulations and the Regulatory Processes in Japan
Japan’s Use of ICH Standards/Principles
Marketing Authorization Processes – Filings & Registrations
Variations: Changes to Marketed Products
The Do’s and Don’ts of Regulatory Involvement

Views: 8


You need to be a member of Online Safety Community to add comments!

Join Online Safety Community

Take our poll!

Take our poll!

Latest Activity

kate smith posted blog posts
2 hours ago
Stevenson University posted a blog post

Social Media Do's And Don'ts

Stevenson University offers a wide range of graduate and professional study options.See More
Profile IconPrarthana J V, Tejaswi Sharma, Stevenson University and 1 more joined Online Safety Community
kate smith posted a blog post

An Explanation of the D.I.S.C. Personality Assessment

A 100-employee business spends an average downtime of 17 hours a week on just clarifying communications. In the process, it ends up losing over half a million dollars annually on this exercise. The reason: Lack of effective communication. This is at the heart of the problems that most organizations face. About 70% of small to mid-size businesses admit that communication is their primary problem.   The cost of…See More


Snowflake and Star Schema in Qlikview

In big name schema all of the facts are stored in one important table and the usage of number one key and overseas key courting different measurement tables are related with the fact desk.SNOWFLAKE…Continue

Tags: processing, transactional, qlikview

Started by Soujanya Naganuri on Tuesday.

What is Class Structure in Pega?

Class contains the rule by way of which objects behave. outline rules such as houses, sports, flows, html paperwork, etc. to be had to different subordinate classes. lessons are organized into a…Continue

Started by Soujanya Naganuri Jul 17.

How to Concatenate Two Tables in QlikView

Table combining and concatenationConcatenate appends the rows of one table to another. Concatenate never merges any rows. The number of rows in a concatenated table is always the sum of the rows of…Continue

Tags: datafields, developers, qlikview

Started by Soujanya Naganuri Jun 30.

SQL Server Windows Management Instrumentation Tasks

Hello,SSIS includes two special tasks that enable you to query system information and monitor system events: the WMI Data Reader Task and the WMI Event Watcher Task. These tasks are especially useful…Continue

Tags: Task, WMI, Server, SQL

Started by Madison Quinn Jun 20.

difference between NEBOSH and IOSH

NEBOSH “National Examination Board in Occupational Health and Safety”IOSH “Institution…Continue

Tags: kerala, IGC, NEBOSH

Started by mani May 31.



© 2017   Created by Safety Community.   Powered by

Badges  |  Report an Issue  |  Terms of Service